Premorbid obesity and metabolic disturbances as promising clinical targets for the prevention and early screening of bipolar disorder

Medical Hypotheses

Volumn 84, Issue 4, 2015, Pages 285-293

  Gálvez, Juan F ^a,b   Sanches, Marsal ^a   Bauer, Isabelle E ^a   Sharma, Ajaykumar N ^a   Hamilton, Jane ^a   Mwangi, Benson ^a   Quevedo, Joao ^a,c   Zunta Soares, Giovana ^a   Soares, Jair C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Facultad de Medicina   (Colombia)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOLOGICAL RHYTHM; BIPOLAR DISORDER; COGNITION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; HUMAN; HYPOTHESIS; INFLAMMATION; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBID OBESITY; NEUROIMAGING; OXIDATIVE STRESS; PREMORBID OBESITY; RISK FACTOR; SCREENING; ADULT; BIOLOGICAL MODEL; COMPLICATION; METABOLISM; OBESITY;

ADULT; BIOMARKERS; BIPOLAR DISORDER; HUMANS; METABOLIC DISEASES; MODELS, BIOLOGICAL; OBESITY;

EID: 84924025924     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.01.016     Document Type: Article

References (112)

1. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010, 12(4):404-413.
2. McIntyre R.S., Konarski J.Z., Yatham L.N. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol 2004, 19(6):369-386.
3. Soreca I., Fagiolini A., Frank E., Houck P.R., Thompson W.K., Kupfer D.J. Relationship of general medical burden, duration of illness and age in bipolar disorder. J Psychiatr Res 2008, 42(11):956-961.
4. Goldstein B.I., Fagiolini A., Houck P., Kupfer D.J. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009, 11(6):657-662.
5. Gomes F., Telo D.F., Souza H.P., Nicolau J.C., Halpern A., Serrano C.V. [Obesity and coronary artery disease: role of vascular inflammation]. Arq Bras Cardiol 2010, 94(2). 255-61, 273-9, 260-6.
6. Hudson J.I., Hiripi E., Pope H.G., Kessler R.C. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007, 61(3):348-358.
7. Lopresti A.L., Drummond P.D. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:92-99.
8. Calkin C., van de Velde C., Růzicková M., et al. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar Disord 2009, 11(6):650-656.
9. Ramsey C.M., Spira A.P., Mojtabai R., Eaton W.W., Roth K., Lee H.B. Lifetime manic spectrum episodes and all-cause mortality: 26-year follow-up of the NIMH epidemiologic catchment area study. J Affect Disord 2013, 151(1):337-342.
10. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L., Miller D.D., Haynes W.G. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008, 20(3):131-137.
11. Dadić-Hero E., Ruzić K., Grahovac T., Petranović D., Graovac M., Palijan T.Z. Metabolic syndrome - the consequence of lifelong treatment of bipolar affective disorder. Psychiatr Danub 2010, 22(2):381-384.
12. Bond D.J., Kunz M., Torres I.J., Lam R.W., Yatham L.N. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord 2010, 12(6):616-626.
13. McIntyre R.S., Cha D.S., Jerrell J.M., et al. Advancing biomarker research: utilizing 'Big Data' approaches for the characterization and prevention of bipolar disorder. Bipolar Disord 2013, [E-pub ahead of print].
14. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004, 65(5):634-651.
15. Goldstein B.I., Liu S.M., Schaffer A., Sala R., Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord 2013, 15(3):284-293.
16. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 2012, 49(2):89-95.
17. Cai D. Central mechanisms of obesity and related metabolic diseases. Rev Endocr Metab Disord 2013, 14(4):309-310.
18. Rodríguez-Hernández H., Simental-Mendía L.E., Rodríguez-Ramírez G., Reyes-Romero M.A. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013, [ID: 678159, E-pub ahead of print].
19. Fan J., Song Y., Chen Y., Hui R., Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol 2013, 168(5):4761-4768.
20. Pedrosa F., Weber M.M., Burgmair W. Ernst Kretschmer (1888-1964). Am J Psychiatry 2002, 159(7):1111.
21. Kretschmer E. Body Structure and Character (Ger) 1921, J. Springer, Berlin.
22. Cai D. Neuroinflammation and neurodegeneration in overnutrition-induced diseases. Trends Endocrinol Metab 2013, 24(1):40-47.
23. Harvey A.G., Talbot L.S., Gershon A. Sleep disturbances in bipolar disorder across the lifespan. Clin Psychol (New York) 2009, 16(2):256-277.
24. Harvey A.G. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008, 165(7):820-829.
25. Andreazza A.C., Andersen M.L., Alvarenga T.A., de-Oliveira M.R., Armari F., Ruiz F.S., et al. Impairment of the mitochondrial electron transport chain due to sleep deprivation in mice. J Psychiatr Res 2010, 44(12):775-880.
26. Giglio L.M., Andreazza A.C., Andersen M., Ceresér K.M., Walz J.C., Sterz L., et al. Sleep in bipolar patients. Sleep Breath 2009, 13(2):169-173.
27. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013, 159(11):758-769.
28. Simon G.E., Von Korff M., Saunders K., Miglioretti D.L., Crane P.K., van Belle G., et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006, 63(7):824-830.
29. Liang J., Matheson B.E., Kaye W.H., Boutelle K.N. Neurocognitive correlates of obesity and obesity-related behaviors in children and adolescents. Int J Obes (Lond) 2014, 38(4):494-506.
30. Yau P.L., Javier D.C., Ryan C.M., Tsui W.H., Ardekani B.A., Ten S., et al. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 2010, 53(11):2298-2306.
31. Yau P.L., Castro M.G., Tagani A., Tsui W.H., Convit A. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics 2012, 130(4):856-864.
32. Segura B., Jurado M.A., Freixenet N., Falcón C., Junqué C., Arboix A. Microstructural white matter changes in metabolic syndrome: a diffusion tensor imaging study. Neurology 2009, 73(6):438-444.
33. Segura B., Jurado M.A., Freixenet N., Bargalló N., Junqué C., Arboix A. White matter fractional anisotropy is related to processing speed in metabolic syndrome patients: a case-control study. BMC Neurol 2010, 10:64.
34. Duffy A., Alda M., Hajek T., Grof P. Early course of bipolar disorder in high-risk offspring: prospective study. Br J Psychiatry 2009, 195(5):457-458.
35. Castilla-Puentes R., Sala R., Ng B., Gálvez J., Camacho A. Anxiety disorders and rapid cycling: data from a cohort of 8129 youths with bipolar disorder. J Nerv Ment Dis 2013, 201(12):1060-1065.
36. Fagiolini A., Chengappa K.N., Soreca I., Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008, 22(8):655-669.
37. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213(1-2):93-118.
38. Konarski J.Z., McIntyre R.S., Kennedy S.H., Rafi-Tari S., Soczynska J.K., Ketter T.A. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 2008, 10(1):1-37.
39. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66(5):407-414.
40. Arnone D., Cavanagh J., Gerber D., Lawrie S.M., Ebmeier K.P., McIntosh A.M. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry 2009, 195(3):194-201.
41. Lorenzetti V., Allen N.B., Fornito A., Yücel M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 2009, 117(1-2):1-17.
42. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Goldstein R.Z., Alia-Klein N., et al. Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity (Silver Spring) 2009, 17(1):60-65.
43. Wang G.J., Volkow N.D., Thanos P.K., Fowler J.S. Imaging of brain dopamine pathways: implications for understanding obesity. J Addict Med 2009, 3(1):8-18.
44. Stoeckel L.E., Kim J., Weller R.E., Cox J.E., Cook E.W., Horwitz B. Effective connectivity of a reward network in obese women. Brain Res Bull 2009, 79(6):388-395.
45. Taki Y., Kinomura S., Sato K., et al. Relationship between body mass index and gray matter volume in 1,428 healthy individuals. Obesity (Silver Spring) 2008, 16(1):119-124.
46. Pannacciulli N., Del Parigi A., Chen K., Le D.S., Reiman E.M., Tataranni P.A. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 2006, 31(4):1419-1425.
47. Sala M., de Roos A., van den Berg A., et al. Microstructural brain tissue damage in metabolic syndrome. Diabetes Care 2014, 37(2):493-500.
48. Bond D.J., Lang D.J., Noronha M.M., et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry 2011, 70(4):381-387.
49. Frank S., Lee S., Preissl H., Schultes B., Birbaumer N., Veit R. The obese brain athlete: self-regulation of the anterior insula in adiposity. PLoS ONE 2012, 7(8):e42570.
50. Bond D.J., Ha T.H., Lang D.J., Torres I.J., Honer W.G., Lam R.W., et al. Body mass index-related regional gray and white matter volume reductions in first-episode mania patients. Biol Psychiatry 2013, [pii: S0006-3223(13)00812-3, Epub ahead of print]. 10.1016/j.biopsych.2013.08.030.
51. Shimoji K., Abe O., Uka T., Yasmin H., Kamagata K., Asahi K., et al. White matter alteration in metabolic syndrome: diffusion tensor analysis. Diabetes Care 2013, 36(3):696-700.
52. Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., Liauw S.S., Alsuwaidan M., Yim C.Y., et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med 2011, 13(6):93-116.
53. Tomasi D., Wang G.J., Wang R., et al. Association of body mass and brain activation during gastric distention: implications for obesity. PLoS ONE 2009, 4(8):e6847.
54. Volkow N.D., Wise R.A. How can drug addiction help us understand obesity?. Nat Neurosci 2005, 8(5):555-560.
55. McIntyre R.S., Danilewitz M., Liauw S.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010, 126(3):366-387.
56. Ising M., Holsboer F. Genetics of stress response and stress-related disorders. Dialog Clin Neurosci 2006, 8(4):433-444.
57. Garaulet M., Lee Y.C., Shen J., et al. CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr 2009, 90(6):1466-1475.
58. Husse J., Hintze S.C., Eichele G., Lehnert H., Oster H. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption. PLoS ONE 2012, 7(12):e52983.
59. Barclay J.L., Husse J., Bode B., et al. Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork. PLoS ONE 2012, 7(5):e37150.
60. Lohoff F.W., Sander T., Ferraro T.N., Dahl J.P., Gallinat J., Berrettini W.H. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2005, 139B(1):51-53.
61. Kremeyer B., Herzberg I., Garcia J., et al. Transmission distortion of BDNF variants to bipolar disorder type I patients from a South American population isolate. Am J Med Genet B Neuropsychiatr Genet 2005, 141B(5):435-439.
62. Grande I., Magalhães P.V., Chendo I., et al. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand 2014 May, 129(5):393-400.
63. Golden E., Emiliano A., Maudsley S., et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS ONE 2010, 5(4):e10099.
64. Kaplan D.R., Miller F.D. Developing with BDNF: a moving experience. Neuron 2007, 55(1):1-2.
65. Winham S.J., Cuellar-Barboza A.B., Oliveros A., et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry 2013, [Epub ahead of print]. 10.1038/mp.2013.159.
66. Danquah I., Othmer T., Frank L.K., Bedu-Addo G., Schulze M.B., Mockenhaupt F.P. The TCF7L2 rs7903146 (T) allele is associated with type 2 diabetes in urban Ghana: a hospital-based case-control study. BMC Med Genet 2013, 14:96.
67. Ferreira M.A., O'Donovan M.C., Meng Y.A., et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008, 40(9):1056-1058.
68. Lee M.T., Chen C.H., Lee C.S., et al. Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol Psychiatry 2011, 16(5):548-556.
69. Sklar P., Smoller J.W., Fan J., et al. Whole-genome association study of bipolar disorder. Mol Psychiatry 2008, 13(6):558-569.
70. Bigos K.L., Mattay V.S., Callicott J.H., et al. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry 2010, 67(9):939-945.
71. Hennah W., Thomson P., McQuillin A., et al. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 2009, 14(9):865-873.
72. Biernacka J.M., McElroy S.L., Crow S., et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord 2012, 136(1-2):21-29.
73. Jiang H.Y., Qiao F., Xu X.F., Yang Y., Bai Y., Jiang L.L. Meta-analysis confirms a functional polymorphism (5-HTTLPR) in the serotonin transporter gene conferring risk of bipolar disorder in European populations. Neurosci Lett 2013, 549:191-196.
74. Wang T.Y., Lee S.Y., Chen S.L., et al. Gender-specific association of the SLC6A4 and DRD2 gene variants in bipolar disorder. Int J Neuropsychopharmacol 2014, 17(2):211-222.
75. Purkayastha S., Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab 2013, 2(4):356-363.
76. Anty R., Bekri S., Luciani N., et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol 2006, 101(8):1824-1833.
77. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444(7121):860-867.
78. Rao S.R. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res 2012, 61(8):789-807.
79. Lima M.M., Pareja J.C., Alegre S.M., et al. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. Obesity (Silver Spring) 2013, 21(3):E182-E189.
80. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, 29:415-445.
81. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011, 121(6):2111-2117.
82. Cai D. One step from prediabetes to diabetes: hypothalamic inflammation?. Endocrinology 2012, 153(3):1010-1013.
83. Cai D., Liu T. Hypothalamic inflammation: a double-edged sword to nutritional diseases. Ann N Y Acad Sci 2011, 1243:1-39.
84. Kapczinski F., Vieta E., Andreazza A.C., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32(4):675-692.
85. Duffy A., Lewitzka U., Doucette S., Andreazza A., Grof P. Biological indicators of illness risk in offspring of bipolar parents: targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry 2012, 6(2):128-137.
86. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013, 74(1):15-25.
87. Desbriere R., Vuaroqueaux V., Achard V., et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006, 14(5):794-798.
88. Mattsson C., Reynolds R.M., Simonyte K., Olsson T., Walker B.R. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. J Clin Endocrinol Metab 2009, 94(4):1347-1352.
89. Jiménez A., Perea V., Corcelles R., Moizé V., Lacy A., Vidal J. Metabolic effects of bariatric surgery in insulin-sensitive morbidly obese subjects. Obes Surg 2013, 23(4):494-500.
90. Stote K.S., Clevidence B.A., Novotny J.A., Henderson T., Radecki S.V., Baer D.J. Effect of cocoa and green tea on biomarkers of glucose regulation, oxidative stress, inflammation and hemostasis in obese adults at risk for insulin resistance. Eur J Clin Nutr 2012, 66(10):1153-1159.
91. Buchowski M.S., Hongu N., Acra S., Wang L., Warolin J., Roberts L.J. Effect of modest caloric restriction on oxidative stress in women, a randomized trial. PLoS ONE 2012, 7(10):e47079.
92. Vincent H.K., Taylor A.G. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006, 30(3):400-418.
93. Limberg J.K., Harrell J.W., Johansson R.E., et al. Microvascular function in younger adults with obesity and metabolic syndrome: role of oxidative stress. Am J Physiol Heart Circ Physiol 2013, 305(8):1230-1237.
94. Petersson H., Risérus U., McMonagle J., et al. Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study. Br J Nutr 2010, 104(9):1357-1362.
95. Schneider R., Meusel M., Betz B., et al. Nitric oxide-induced regulation of renal organic cation transport after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2001, 301(5):997-1004.
96. de Góis Queiroz A.I., Medeiros C.D., Ribeiro B.M., de Lucena D.F., Macêdo D.S. Angiotensin receptor blockers for bipolar disorder. Med Hypotheses 2013, 80(3):259-263.
97. Das U.N. Angiotensin-II behaves as an endogenous pro-inflammatory molecule. J Assoc Phys India 2005, 53:472-476.
98. Kapczinski F., Dias V., Kauer-Sant' Anna M., Frey B., Grassi-Oliveira R., Colom F., et al. Clinical implications of staging model for bipolar disorders. Exp Rev Neurother 2009, 9(7):957-966.
99. Wakai T., Yoshioka H., Yagi T., Kato T., Kinouchi H. Effects of valsartan on neuroprotection and neurogenesis after ischemia. NeuroReport 2011, 22:385-390.
100. Malhi G.S., Bargh D.M., Couston C.M., Das P., Berk M. Predicting bipolar disorder on the basis of phenomenology: implications for prevention and early intervention. Bipolar Disord 2013, [Epub ahead of print]. 10.1111/bdi.12133.
101. Bechdolf A., Ratheesh A., Wood S.J., Tecic T., Conus P., Nelson B., et al. Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. Curr Pharm Des 2012, 18(4):358-375.
102. Leopold K., Ratzer S., Correll C.U., Rottmann-Wolf M., Pfeiffer S., Ritter P., et al. Characteristics, symptomatology and naturalistic treatment in individuals at-risk for bipolar disorders: baseline results in the first 180 help-seeking individuals assesses at the Dresden high-risk project. J Affect Disord 2014, 152-154:427-433.
103. Duffy A., Horrocks J., Milin R., Doucette S., Persson G., Grof P. Adolescent substance use disorder during early stages of bipolar disorder: a prospective high-risk study. J Affect Disord 2012, 142(1-3):57-64.
104. Megna J.L., Schwartz T.L., Siddiqui U.A., Herrera Rojas M. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry 2011, 23(2):131-140.
105. Bradford D.W., Cunningham N.T., Slubicki M.N., et al. An evidence synthesis of care models to improve general medical outcomes for individuals with serious mental illness: a systematic review. J Clin Psychiatry 2013, 74(8):754-764.
106. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70(8):1078-1090.
107. Berk M., Bmabic A., Dodd S., Kelin K., Tohen M., Malhi G.S., et al. Does stage of illness impact treatment response in bipolar disorder? Empirical data and their implication for staging model and early intervention. Bipolar Disord 2011, 13(1):87-98.
108. Quinones M.P., Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009, 35(2):165-176.
109. Fu Y., Mukhamedova N., Ip S., et al. ABCA12 regulates ABCA1-dependent cholesterol efflux from macrophages and the development of atherosclerosis. Cell Metab 2013, 18(2):225-238.
110. Zhang A.H., Qiu S., Xu H.Y., Sun H., Wang X.J. Metabolomics in diabetes. Clin Chim Acta 2014, 429:106-110.
111. Gariepy G., Nitka D., Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes (Lond) 2010, 34(3):407-419.
112. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., et al. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J Affect Disord 2012, 141(1):1-10.